Dominick Angiolillo, Adnan Kastrati, Daniel Simon

• List of Contributors. Foreword. Preface. Color Plates. Section I Basic Concepts of Atherothrombosis. 1. Fundamentals of the Thrombosis Cascade: Interaction Between Platelets and the Coagulation Cascade. 2. Platelet Receptors and Their Role in Atherothrombosis. 3. Laboratory Assessment of Platelet Function and Coagulation. Section II: Antithrombotic drugs. II.A: Oral Antiplatelet Drugs. 4. Cyclooxygenase Inhibition in Atherothrombotic Disease. 5. P2Y12 Receptor Antagonism: From Bench to Bedside. 6. Timing, Dosing and Length of Clopidogrel Therapy. 7. Resistance to Antiplatelet Drugs: Aspirin. 8. Resistance to Antiplatelet Drugs: Clopidogrel. 9. Prasugrel – a Third-Generation Thienopyridine. 10. Direct oral P2Y12 Inhibition: AZD6140 (Ticagrelor). 11. Emerging Oral Antiplatelet Receptor Inhibitors. II.B Intravenous Antiplatelet Drugs. 12. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Fundamental and Pharmacological Aspects. 13. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: a Guide to Patient Selection and Optimal Use. 14. Cangrelor. II.C Thrombin Inhibitors and Thrombin Generation Inhibitors. 15. Indirect Thrombin Inhibitors: Fundamentals and Guide to Optimal Therapy Using. Unfractionated Heparin and Low-Molecular-Weight Heparins. 16. Direct Thrombin Inhibitors. 17. Fondaparinux in Acute Coronary Syndromes. 18. Tissue Factor Inhibitors. II.D: Fibrinolytic Therapy. 19. Fibrinolytics: Current Indications and Treatment Modalities in the Absence of Mechanical Reperfusion. 20. Fibrinolytics and Percutaneous Coronary Intervention. Section III Special Situations. 21. Role of Facilitated Percutaneous Coronary Intervention in ST-elevation Myocardial Infarction. 22. Antithrombotic Treatment in Vein Graft Interventions. 23. Antiplatelet Therapy in Diabetes Mellitus. 24. Stent Thrombosis in the Era of Drug-Eluting Stents. 25. Bleeding Complications: Anticoagulant and Antiplatelet Therapy Control. 26. Heparin-Induced Thrombocytopenia: Etiopathogenesis, Clinical Presentation, and Management. 27. Antithrombotic Therapies for Patients with Cerebrovascular, Peripheral Arterial, and Coronary Artery Disease. 28. Dual Antiplatelet Strategies in Patients Requiring Vitamin K Antagonists. Appendix. Index.

Dominick Angiolillo, Adnan Kastrati, Daniel Simon

• List of Contributors. Foreword. Preface. Color Plates. Section I Basic Concepts of Atherothrombosis. 1. Fundamentals of the Thrombosis Cascade: Interaction Between Platelets and the Coagulation Cascade. 2. Platelet Receptors and Their Role in Atherothrombosis. 3. Laboratory Assessment of Platelet Function and Coagulation. Section II: Antithrombotic drugs. II.A: Oral Antiplatelet Drugs. 4. Cyclooxygenase Inhibition in Atherothrombotic Disease. 5. P2Y12 Receptor Antagonism: From Bench to Bedside. 6. Timing, Dosing and Length of Clopidogrel Therapy. 7. Resistance to Antiplatelet Drugs: Aspirin. 8. Resistance to Antiplatelet Drugs: Clopidogrel. 9. Prasugrel – a Third-Generation Thienopyridine. 10. Direct oral P2Y12 Inhibition: AZD6140 (Ticagrelor). 11. Emerging Oral Antiplatelet Receptor Inhibitors. II.B Intravenous Antiplatelet Drugs. 12. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Fundamental and Pharmacological Aspects. 13. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: a Guide to Patient Selection and Optimal Use. 14. Cangrelor. II.C Thrombin Inhibitors and Thrombin Generation Inhibitors. 15. Indirect Thrombin Inhibitors: Fundamentals and Guide to Optimal Therapy Using. Unfractionated Heparin and Low-Molecular-Weight Heparins. 16. Direct Thrombin Inhibitors. 17. Fondaparinux in Acute Coronary Syndromes. 18. Tissue Factor Inhibitors. II.D: Fibrinolytic Therapy. 19. Fibrinolytics: Current Indications and Treatment Modalities in the Absence of Mechanical Reperfusion. 20. Fibrinolytics and Percutaneous Coronary Intervention. Section III Special Situations. 21. Role of Facilitated Percutaneous Coronary Intervention in ST-elevation Myocardial Infarction. 22. Antithrombotic Treatment in Vein Graft Interventions. 23. Antiplatelet Therapy in Diabetes Mellitus. 24. Stent Thrombosis in the Era of Drug-Eluting Stents. 25. Bleeding Complications: Anticoagulant and Antiplatelet Therapy Control. 26. Heparin-Induced Thrombocytopenia: Etiopathogenesis, Clinical Presentation, and Management. 27. Antithrombotic Therapies for Patients with Cerebrovascular, Peripheral Arterial, and Coronary Artery Disease. 28. Dual Antiplatelet Strategies in Patients Requiring Vitamin K Antagonists. Appendix. Index.

Dominick Angiolillo, Adnan Kastrati, Daniel Simon

• List of Contributors. Foreword. Preface. Color Plates. Section I Basic Concepts of Atherothrombosis. 1. Fundamentals of the Thrombosis Cascade: Interaction Between Platelets and the Coagulation Cascade. 2. Platelet Receptors and Their Role in Atherothrombosis. 3. Laboratory Assessment of Platelet Function and Coagulation. Section II: Antithrombotic drugs. II.A: Oral Antiplatelet Drugs. 4. Cyclooxygenase Inhibition in Atherothrombotic Disease. 5. P2Y12 Receptor Antagonism: From Bench to Bedside. 6. Timing, Dosing and Length of Clopidogrel Therapy. 7. Resistance to Antiplatelet Drugs: Aspirin. 8. Resistance to Antiplatelet Drugs: Clopidogrel. 9. Prasugrel – a Third-Generation Thienopyridine. 10. Direct oral P2Y12 Inhibition: AZD6140 (Ticagrelor). 11. Emerging Oral Antiplatelet Receptor Inhibitors. II.B Intravenous Antiplatelet Drugs. 12. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Fundamental and Pharmacological Aspects. 13. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: a Guide to Patient Selection and Optimal Use. 14. Cangrelor. II.C Thrombin Inhibitors and Thrombin Generation Inhibitors. 15. Indirect Thrombin Inhibitors: Fundamentals and Guide to Optimal Therapy Using. Unfractionated Heparin and Low-Molecular-Weight Heparins. 16. Direct Thrombin Inhibitors. 17. Fondaparinux in Acute Coronary Syndromes. 18. Tissue Factor Inhibitors. II.D: Fibrinolytic Therapy. 19. Fibrinolytics: Current Indications and Treatment Modalities in the Absence of Mechanical Reperfusion. 20. Fibrinolytics and Percutaneous Coronary Intervention. Section III Special Situations. 21. Role of Facilitated Percutaneous Coronary Intervention in ST-elevation Myocardial Infarction. 22. Antithrombotic Treatment in Vein Graft Interventions. 23. Antiplatelet Therapy in Diabetes Mellitus. 24. Stent Thrombosis in the Era of Drug-Eluting Stents. 25. Bleeding Complications: Anticoagulant and Antiplatelet Therapy Control. 26. Heparin-Induced Thrombocytopenia: Etiopathogenesis, Clinical Presentation, and Management. 27. Antithrombotic Therapies for Patients with Cerebrovascular, Peripheral Arterial, and Coronary Artery Disease. 28. Dual Antiplatelet Strategies in Patients Requiring Vitamin K Antagonists. Appendix. Index.